Amedisys (NASDAQ:AMED) Lowered to “Buy” Rating by Wall Street Zen
Amedisys (NASDAQ:AMED – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday. A number of other research firms also recently weighed in on AMED. Royal Bank of Canada restated an “outperform” rating and issued a […]
Amedisys (NASDAQ:AMED – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday. A number of other research firms also recently weighed in on AMED. Royal Bank of Canada restated an “outperform” rating and issued a […]
